Jeremy M Palmer Selected Research

Pyruvate Dehydrogenase Complex (Dehydrogenase Complex, Pyruvate)

11/2018	Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis.
12/2008	Xenobiotic incorporation into pyruvate dehydrogenase complex can occur via the exogenous lipoylation pathway.
9/2008	Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis.
5/2006	PDC-E3BP is not a dominant T-cell autoantigen in primary biliary cirrhosis.
5/2005	A key role for autoreactive B cells in the breakdown of T-cell tolerance to pyruvate dehydrogenase complex in the mouse.
6/2004	Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse.
12/2002	Oral tolerisation to pyruvate dehydrogenase complex as a potential therapy for primary biliary cirrhosis.
2/2002	Investigation of a mechanism for accelerated breakdown of immune tolerance to the primary biliary cirrhosis-associated autoantigen, pyruvate dehydrogenase complex.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeremy M Palmer Research Topics

Disease

12	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2021 - 02/2002
6	Liver Diseases (Liver Disease) 01/2021 - 02/2002
2	Inflammation (Inflammations) 01/2022 - 03/2012
2	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2017
1	Premature Birth (Birth, Premature) 10/2022
1	Enterocolitis 10/2022
1	Infections 10/2022
1	Fatty Liver 01/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Obesity 01/2022
1	Autoimmune Diseases (Autoimmune Disease) 11/2017
1	Disease Progression 11/2017
1	Cholangiocarcinoma 01/2016
1	Rheumatoid Arthritis 03/2012
1	Acidosis 09/2008
1	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 09/2008
1	Mitochondrial Diseases (Mitochondrial Disease) 09/2008

Drug/Important Bio-Agent (IBA)

8	Pyruvate Dehydrogenase Complex (Dehydrogenase Complex, Pyruvate)IBA 11/2018 - 02/2002
3	AntigensIBA 12/2008 - 05/2006
2	LipidsIBA 01/2022 - 01/2017
2	Ionic LiquidsIBA 01/2021 - 02/2020
2	Thioctic Acid (Lipoic Acid)IBA 11/2018 - 12/2008
2	EnzymesIBA 12/2008 - 02/2002
2	AutoantibodiesIBA 09/2008 - 05/2006
2	AutoantigensIBA 05/2006 - 02/2002
1	Immunoglobulin A (IgA)IBA 10/2022
1	Secretory Immunoglobulin A (SIgA)IBA 10/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	SugarsIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2022
1	AntibodiesIBA 11/2018
1	XenobioticsIBA 11/2018
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 11/2018
1	Tryptophan (L-Tryptophan)FDA Link 11/2017
1	Biomarkers (Surrogate Marker)IBA 11/2017
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 11/2017
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2017
1	estragole (methyl chavicol)IBA 01/2016
1	1'-hydroxyestragoleIBA 01/2016
1	ChemokinesIBA 03/2012
1	Chemokine ReceptorsIBA 03/2012
1	EpitopesIBA 12/2008
1	Adenosine Diphosphate (ADP)IBA 09/2008
1	Phosphocreatine (Neoton)IBA 09/2008
1	Bacterial DNAIBA 09/2002

Therapy/Procedure

2	Therapeutics 01/2022 - 12/2002